Clinical Cancer Research · 2008 · 44 citations · 37 references
MedicineGeneticsOncologyCancer GeneticsCarcinogenesisMolecular OncologyAndrogen Deprivation TherapyCancer GenomicsHormonal TherapyHormone Receptor GeneticsOncogenic Signaling PathwaysProstate CancerAndrogen Deprivation Therapy ResistanceAnti-androgen ResistanceEpidermal Growth Factor Receptor SignalingGenetic Susceptibility To Prostate CancerHormone Resistance MechanismsProstate CarcinogenesisSingle-nucleotide Polymorphism Analysis
PURPOSE: Most prostate cancer patients develop resistance to androgen deprivation treatment, resulting in hormone resistance. Epidermal growth factor (EGF) activates several pro-oncogenic intracellular pathways inducing proliferation, differentiation, and tumorigenesis in epithelial cells. The EGF-EGF receptor pathway seems to be especially relevant in hormone-resistant prostate cancer stage. A single nucleotide polymorphism G>A in +61 locus of EGF gene has been described, in which A homozygous carriers express significantly less EGF protein compared with G allele carriers. Our purpose was to investigate the potential prognostic and predictive role of EGF functional genetic variant +61 G>A in prostate cancer patients submitted to androgen blockade therapy (ABT). EXPERIMENTAL DESIGN: We conducted a case-control study in prostate cancer patients treated with ABT (n = 123) and in healthy controls without evidence of cancer (n = 152). Cumulatively, a follow-up study (median follow-up, 37 months) was undertaken to evaluate response to ABT therapy in prostate cancer patients. EGF +61 G>A genotypes were detected by PCR-RFLP. RESULTS: We found increased risk in G carriers, after age-adjusted regression analysis, for being diagnosed with Gleason > or =7 and with metastatic disease compared with control group (CG; age-adjusted odds ratio, 3.37, P = 0.004 and age-adjusted odds ratio, 2.61, P = 0.043, respectively). Kaplan-Meier survival analysis and log-rank test showed an influence of EGF +61 G>A polymorphism in time to relapse during ABT (P = 0.018). CONCLUSIONS: EGF functional polymorphism may contribute to earlier relapse in ABT patients, supporting the involvement of EGF as an alternative pathway in hormone-resistant prostatic tumors. Furthermore, our results lend support to EGF-EGF receptor pathway as an additional therapeutic target during hormonal treatment.
37
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Tapio Visakorpi, Eija Hyytinen, Pasi A. Koivisto et al. · Nature Genetics · 1995 · 1.5K citations
Integrative molecular concept modeling of prostate cancer progression
Scott A. Tomlins, Rohit Mehra, Daniel R. Rhodes et al. · Nature Genetics · 2006 · 937 citations
Activation of Phosphoinositide 3-OH Kinase by the α6β4 Integrin Promotes Carcinoma Invasion
Isaac Rabinovitz, Helen H.-F Wang, Alex Toker et al. · Cell · 1997 · 616 citations · Full text